Refine your search
Collections
Co-Authors
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Ranga, Udaykumar
- Inducing Quality Immune Response to Respiratory Viruses May Not Be a Simple Task
Abstract Views :198 |
PDF Views:72
Authors
Affiliations
1 HIV-AIDS Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur (PO), Bengaluru 560 064, IN
1 HIV-AIDS Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Jakkur (PO), Bengaluru 560 064, IN
Source
Current Science, Vol 120, No 8 (2021), Pagination: 1315-1323Abstract
A few front-runner vaccines for COVID-19 have reported over 90% protection in phase II/III clinical trials, raising hopes. These studies, however, have evaluated only a relative, not absolute, protection. The leading COVID-19 vaccines have been designed to elicit a systemic, not mucosal, immune response. While a systemic immune response may reduce disease severity, only the mucosal immune response can reduce the spreading of a respiratory viral infection. Here, we explain why inducing long-lasting and high-quality immune response to mucosal infections is typically challenging. A few possible solutions are proposed.Keywords
COVID-19 Vaccines, Clinical Trials, Respiratory Viral Infection, Systemic and Mucosal Immune Response.Full Text
References
- Amanna, I. J. and Slifka, M. K., Successful vaccines. Curr. Top. Microbiol., 2020, 428, 1–30.
- Thursby, E. and Juge, N., Introduction to the human gut microbiota. Biochem. J., 2017, 474(11), 1823–1836.
- Hammarlund, E., Lewis, M. W., Hanifin, J. M., Mori, M., Koudelka, C. W. and Slifka, M. K., Antiviral immunity following smallpox virus infection: a case-control study. J. Virol., 2010, 84(24), 12754–12760.
- Cevik, M., Kuppalli, K., Kindrachuk, J. and Peiris, M., Virology, transmission, and pathogenesis of SARS-CoV-2. Br. Med. J., 2020, 371, 3862.
- Hilleman, M. R., Strategies and mechanisms for host and pathogen survival in acute and persistent viral infections. Proc. Natl. Acad. Sci. USA, 2004, 101(Suppl 2), 14560–14566.
- Mowat, A. M., To respond or not to respond – a personal perspective of intestinal tolerance. Nature Rev. Immunol., 2018, 18(6), 405–415.
- Holt, P. G., Strickland, D. H., Wikström, M. E. and Jahnsen, F. L., Regulation of immunological homeostasis in the respiratory tract. Nature Rev. Immunol., 2008, 8(2), 142–152.
- Moreno-Fierros, L., García-Silva, I. and Rosales-Mendoza, S., Development of SARS-CoV-2 vaccines: should we focus on mucosal immunity? Exp. Opinion Biol. Therapy, 2020, 20(8), 831–836.
- Hwang, J. Y., Randall, T. D. and Silva-Sanchez, A., Inducible Bronchus-associated lymphoid tissue: taming inflammation in the lung. Front. Immunol., 2016, 7, 258.
- Corthésy, B., Multi-faceted functions of secretory IgA at mucosal surfaces. Front. Immunol., 2013, 4, 185.
- Allie, S. R., Bradley, J. E., Mudunuru, U., Schultz, M. D., Graf, B. A., Lund, F. E. and Randall, T. D., The establishment of resident memory B cells in the lung requires local antigen encounter. Nature Immunol., 2019, 20(1), 97–108.
- Wagner, D. K., Clements, M. L., Reimer, C. B., Snyder, M., Nelson, D. L. and Murphy, B. R., Analysis of immunoglobulin G antibody responses after administration of live and inactivated influenza A vaccine indicates that nasal wash immunoglobulin G is a transudate from serum. J. Clin. Microbiol., 1987, 25(3), 559– 562.
- Vonarburg, C. et al., Topical application of nebulized human IgG, IgA and IgAM in the lungs of rats and non-human primates. Respir. Res., 2019, 20(1), 99.
- Holmgren, J. and Czerkinsky, C., Mucosal immunity and vaccines. Nature Med., 2005, 11(4), S45–S53.
- Valtanen, S., Roivainen, M., Piirainen, L., Stenvik, M. and Hovi, T., Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion. J. Infect. Dis., 2005, 182(1), 1–5.
- Buisman, A. M., Abbink, F., Schepp, R. M., Sonsma, J. A., Herremans, T. and Kimman, T. G., Preexisting poliovirus-specific IgA in the circulation correlates with protection against virus excretion in the elderly. J. Infect. Dis., 2008, 197(5), 698–706.
- Clarke, E. and Desselberger, U., Correlates of protection against human rotavirus disease and the factors influencing protection in low-income settings. Mucosal Immunol., 2015, 8(1), 1–17.
- Baker, J. M., Tate, J. E., Leon, J., Haber, M. J., Pitzer, V. E. and Lopman, B. A., Postvaccination serum antirotavirus immunoglobulin A as a correlate of protection against rotavirus gastroenteritis across settings. J. Infect. Dis., 2020, 222(2), 309–318.
- Jin, C. et al., Vi-specific serological correlates of protection for typhoid fever. J. Exp. Med., 2020, 218(2), e20201116.
- Harris, J. B., Cholera: immunity and prospects in vaccine development. J. Infect. Dis., 2018, 218(3), S141–S146.
- Masomian, M., Ahmad, Z., Ti Gew, L. and Poh, C. L., Development of next generation Streptococcus pneumoniae vaccines conferring broad protection. Vaccines, 2020, 8(1), 132.
- Ruckwardt, T. J., Morabito, K. M. and Graham, B. S., Immunological lessons from respiratory syncytial virus vaccine development. Immunity, 2019, 51(3), 429–442.
- Krammer, F., The human antibody response to influenza A virus infection and vaccination. Nature Rev. Immunol., 2019, 19(6), 383–397.
- Brandtzaeg, P., Role of mucosal immunity in influenza. Dev. Biologic., 2003, 115, 39–48.
- Waffarn, E. E. and Baumgarth, N., Protective B cell responses to flu – no fluke. J. Immunol., 2011, 186(7), 3823–3829.
- Vogel, A. B. et al., Immunogenic BNT162b vaccines protect rhesus macaques from SARS-COV-2. Nature, 2021; doi:10.1038/s41586-021-03275-y
- Corbett, K. S. et al., Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med., 2020, 383(16), 1544–1555.
- van Doremalen, N. et al., ChAdOx1 nCoV-19 vaccination prevents SARS-CoV-2 pneumonia in rhesus macaques. Nature, 2020, 586, 578–582.
- Guebre-Xabier, M. et al., NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge. Vaccine, 2020, 38(50), 7892–7896.
- Mercado, N. B. et al., Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature, 2020, 586(7830), 583– 588.
- Baden, L. R. et al., Efficacy and safety of the mRNA-1273 SARSCoV2 vaccine. N. Engl. J. Med., 2020, 384(5), 403–416.
- Polack, F. P. et al., Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Eng. J. Med., 2020, 383(27), 2603–2615.
- Doshi, P., Will COVID-19 vaccines save lives? Current trials aren’t designed to tell us. Br. Med. J., 2020, 371: m4037; https://pubmed.ncbi.nlm.nih.gov/33087398
- Voysey, M. et al., Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet, 2021, 397(10,269), 99–111.
- Logunov, D. Y. et al., Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. Lancet, 2021, 397, 671–681.
- Lauring, A. S. and Hodcroft, E. B., Genetic variants of SARSCoV2 – what do they mean? J. Am. Med. Assoc., 2021, 325(6), 529–531.
- Moore, J. P. and Offit, P. A., SARS-CoV-2 vaccines and the growing threat of viral variants. J. Am. Med. Assoc., 2021, 325(9), 821– 822.
- Horwitz, M. A., Jia, Q. A., Bielefeldt-Ohmann, H., Maison, R., Maslesa-Galic, S. and Bowen, R. A., Replicating bacteriumvectored vaccine expressing SARS-CoV-2 membrane and nucleocapsid proteins protects against severe COVID-19 disease in hamsters. bioRxiv, 2020.
- Couch, R. B. and Kasel, J. A., Immunity to influenza in man. Annu. Rev. Microbiol., 1983, 37, 529–549.
- Tomar, J., Born, P. A., Frijlink, H. W. and Hinrichs, W. L., Dry influenza vaccines: towards a stable, effective and convenient alternative to conventional parenteral influenza vaccination. Expert Rev. Vaccines, 2016, 15(11), 1431–1447.
- Boyaka, P. N., Inducing mucosal IgA: a challenge for vaccine adjuvants and delivery systems. J. Immunol., 2017, 199(1), 9–16.
- Pallesen, J. et al., Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. USA, 2017, 114(35), E7348–E7357.